Skip to main content
Top
Published in: BMC Medicine 1/2021

Open Access 01-12-2021 | Research article

A systematic assessment of the association between frequently prescribed medicines and the risk of common cancers: a series of nested case-control studies

Authors: R. D. McDowell, C. Hughes, P. Murchie, C. Cardwell

Published in: BMC Medicine | Issue 1/2021

Login to get access

Abstract

Background

Studies systematically screening medications have successfully identified prescription medicines associated with cancer risk. However, adjustment for confounding factors in these studies has been limited. We therefore investigated the association between frequently prescribed medicines and the risk of common cancers adjusting for a range of confounders.

Methods

A series of nested case-control studies were undertaken using the Primary Care Clinical Informatics Unit Research (PCCIUR) database containing general practice (GP) records from Scotland. Cancer cases at 22 cancer sites, diagnosed between 1999 and 2011, were identified from GP records and matched with up to five controls (based on age, gender, GP practice and date of registration). Odds ratios (OR) and 95% confidence intervals (CI) comparing any versus no prescriptions for each of the most commonly prescribed medicines, identified from prescription records, were calculated using conditional logistic regression, adjusting for comorbidities. Additional analyses adjusted for smoking use. An association was considered a signal based upon the magnitude of its adjusted OR, p-value and evidence of an exposure-response relationship. Supplementary analyses were undertaken comparing 6 or more prescriptions versus less than 6 for each medicine.

Results

Overall, 62,109 cases and 276,580 controls were included in the analyses and a total of 5622 medication-cancer associations were studied across the 22 cancer sites. After adjusting for comorbidities 2060 medicine-cancer associations for any prescription had adjusted ORs greater than 1.25 (or less than 0.8), 214 had a corresponding p-value less than or equal to 0.01 and 118 had evidence of an exposure-dose relationship hence meeting the criteria for a signal. Seventy-seven signals were identified after additionally adjusting for smoking. Based upon an exposure of 6 or more prescriptions, there were 118 signals after adjusting for comorbidities and 82 after additionally adjusting for smoking.

Conclusions

In this study a number of novel associations between medicine and cancer were identified which require further clinical and epidemiological investigation. The majority of medicines were not associated with an altered cancer risk and many identified signals reflected known associations between medicine and cancer.
Appendix
Available only for authorised users
Literature
5.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–68.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–68.CrossRef
6.
go back to reference Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:1–57.CrossRef Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:1–57.CrossRef
10.
go back to reference West-Strum D. Chapter 1. Introduction to Pharmacoepidemiology. In: Ynag Y, West-Strum D, editors. Understanding Pharmacoepidemiology. New York: McGraw-Hill Education; 2011. West-Strum D. Chapter 1. Introduction to Pharmacoepidemiology. In: Ynag Y, West-Strum D, editors. Understanding Pharmacoepidemiology. New York: McGraw-Hill Education; 2011.
12.
go back to reference Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980;65:723–33.CrossRef Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980;65:723–33.CrossRef
13.
go back to reference Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst. 1983;71:1165–75.PubMed Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst. 1983;71:1165–75.PubMed
14.
go back to reference Selby J, Friedman G, Fireman B. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49:5736–47.PubMed Selby J, Friedman G, Fireman B. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49:5736–47.PubMed
15.
go back to reference van den Eeden SK, Friedman GD. Prescription drug screening for subsequent carcinogenicity. Pharmacoepidemiol Drug Saf. 1995;4:275–87.CrossRef van den Eeden SK, Friedman GD. Prescription drug screening for subsequent carcinogenicity. Pharmacoepidemiol Drug Saf. 1995;4:275–87.CrossRef
16.
go back to reference Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20:1821–35.CrossRef Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20:1821–35.CrossRef
20.
go back to reference Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget. 2018;9:17420–9.CrossRef Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget. 2018;9:17420–9.CrossRef
23.
go back to reference Busby J, Murchie P, Murray L, Iversen L, Lee AJ, Spence A, et al. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case–control study of routine Scottish data. Int J Cancer. 2017;140:1828–35.CrossRef Busby J, Murchie P, Murray L, Iversen L, Lee AJ, Spence A, et al. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case–control study of routine Scottish data. Int J Cancer. 2017;140:1828–35.CrossRef
24.
go back to reference Macfarlane TV, Lefevre K, Watson MC. Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer. 2014;111:1825–59.CrossRef Macfarlane TV, Lefevre K, Watson MC. Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer. 2014;111:1825–59.CrossRef
25.
go back to reference Tran KT, McMenamin C, Hicks B, Murchie P, Thrift AP, Coleman HG, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018;48:55–64.CrossRef Tran KT, McMenamin C, Hicks B, Murchie P, Thrift AP, Coleman HG, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018;48:55–64.CrossRef
26.
go back to reference Spence AD, Busby J, Murchie P, Kunzmann AT, McMenamin ÚC, Coleman HG, et al. Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: an analysis of two independent population-based databases. Int J Cancer. 2018;143:22–31.CrossRef Spence AD, Busby J, Murchie P, Kunzmann AT, McMenamin ÚC, Coleman HG, et al. Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: an analysis of two independent population-based databases. Int J Cancer. 2018;143:22–31.CrossRef
33.
go back to reference Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, et al. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012;5:1231–8.CrossRef Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, et al. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012;5:1231–8.CrossRef
35.
go back to reference Jespersen CG, Nørgaard M, Borre M. Parkinson’s disease and risk of prostate cancer: a Danish population-based case-control study, 1995-2010. Cancer Epidemiol. 2016;45:157–61.CrossRef Jespersen CG, Nørgaard M, Borre M. Parkinson’s disease and risk of prostate cancer: a Danish population-based case-control study, 1995-2010. Cancer Epidemiol. 2016;45:157–61.CrossRef
38.
go back to reference Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–65.CrossRef Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–65.CrossRef
39.
go back to reference Joint Formulary Committee. British National Formulary. 79th ed. London: BMJ Group and Pharmaceutical Press; 2020. Joint Formulary Committee. British National Formulary. 79th ed. London: BMJ Group and Pharmaceutical Press; 2020.
40.
go back to reference StataCorp. Stata Statistical Software: Release 15. 2017. StataCorp. Stata Statistical Software: Release 15. 2017.
42.
go back to reference Thun MJ, Jane Henley S, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.CrossRef Thun MJ, Jane Henley S, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.CrossRef
44.
go back to reference Lai SW, Lin CL, Liao KF. Actively using clopidogrel correlates with an increased risk of acute pancreatitis in Taiwan. Int J Cardiol. 2015;183:263–6.CrossRef Lai SW, Lin CL, Liao KF. Actively using clopidogrel correlates with an increased risk of acute pancreatitis in Taiwan. Int J Cardiol. 2015;183:263–6.CrossRef
45.
go back to reference Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med. 2009;122:407–8.CrossRef Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med. 2009;122:407–8.CrossRef
48.
go back to reference Barkin RL. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther. 2015;22:388–407.CrossRef Barkin RL. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther. 2015;22:388–407.CrossRef
49.
go back to reference Atkinson MD, Kennedy JI, John A, Lewis KE, Lyons RA, Brophy ST, et al. Development of an algorithm for determining smoking status and behaviour over the life course from UK electronic primary care records. BMC Med Inform Decis Mak. 2017;17:2. Atkinson MD, Kennedy JI, John A, Lewis KE, Lyons RA, Brophy ST, et al. Development of an algorithm for determining smoking status and behaviour over the life course from UK electronic primary care records. BMC Med Inform Decis Mak. 2017;17:2.
51.
go back to reference Bonferroni C. Teoria statistica delle classi e calcolo delle probabilit. Pubbl del R Ist Super di Sci Econ e Commer di Firenze. 1936;8:3–62. Bonferroni C. Teoria statistica delle classi e calcolo delle probabilit. Pubbl del R Ist Super di Sci Econ e Commer di Firenze. 1936;8:3–62.
52.
go back to reference Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995.
53.
go back to reference Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–6.CrossRef Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–6.CrossRef
Metadata
Title
A systematic assessment of the association between frequently prescribed medicines and the risk of common cancers: a series of nested case-control studies
Authors
R. D. McDowell
C. Hughes
P. Murchie
C. Cardwell
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-020-01891-5

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue